Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press5110.17650/1994-4098-2013-0-3-4-18-22MAMMOLOGY. DIAGNOSISМАММОЛОГИЯ. ДИАГНОСТИКАBreast magnetic resonance imaging significance for breast cancer diagnostic in women with genetic predisposition and a strong family historyЗначение магнитно-резонансной томографии молочных желез в диагностике рака молочной железы у женщин с генетической предрасположенностью и отягощенным семейным анамнезомKarpovaM. S.КарповаМ. С.
Russian Federation
mskarpova@bk.ruBudikYu. A.БудикЮ. А.
Russian Federation
KorzhenkovaG. P.КорженковаГ. П.
Russian Federation
LyubchenkoL. N.ЛюбченкоЛ. Н.
Russian Federation
SobolevskiyV. A.СоболевскийВ. А.
Russian Federation
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва220920133-4182222072014220720142013https://ojrs.abvpress.ru/ojrs/article/view/51

Screening of breast cancer with mammography recommended to women over 40 has been shown to decrease breast cancer mortality. But mam- mography has much lower accuracy in young women with BRCA1/2 mutations and women with a strong family history. Therefore new screening methods in young high-risk women are necessary to detect early-stage cancer.

Маммографический скрининг, рекомендованный женщинам старше 40 лет, снижает смертность от рака молочной железы. Но маммография оказалась малоэффективной в группе молодых женщин с отягощенным семейным анамнезом (семейный рак) и носителей мутаций генов BRCA1 и BRCA2. В связи с этим встал вопрос о введении в скрининговую программу женщин высокого риска дополнительных методов, которые бы позволили выявлять рак молочной железы в доклинической стадии.

breast cancermagnetic resonance imagingmammographyBRCA1BRCA2рак молочной железымагнитно-резонансная томографиямаммографияBRCA1BRCA21. Hamilton L.J., Evans A.J., Wilson A.R. et al. Breast imaging findings in women with BRCA1- and BRCA2-associated breast carcinoma. Clin Radiol 2004;59(10):895–902.Hamilton L.J., Evans A.J., Wilson A.R. et al. Breast imaging findings in women with BRCA1- and BRCA2-associated breast carcinoma. Clin Radiol 2004;59(10):895–902.2. Kaas R., Kroger R., Hendriks J.H. et al. The significance of circumscribed malignant mammographic masses in the surveillance of BRCA 1/2 gene mutation carriers. Eur Radiol 2004;14(9):1647–53.Kaas R., Kroger R., Hendriks J.H. et al. The significance of circumscribed malignant mammographic masses in the surveillance of BRCA 1/2 gene mutation carriers. Eur Radiol 2004;14(9):1647–53.3. Veltman J., Mann R., Kok T. et al. Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI. Eur Radiol 2008;18(5):931–8.Veltman J., Mann R., Kok T. et al. Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI. Eur Radiol 2008;18(5):931–8.4. Kuhl C.K., Schrading S., Leutner C.C. et al. Mammography, breast ultrasound, and mag- netic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005;23(33):8469–76.Kuhl C.K., Schrading S., Leutner C.C. et al. Mammography, breast ultrasound, and mag- netic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005;23(33):8469–76.5. Warner E., Plewes D.B., Hill K.A. et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ul- trasound, mammography, and clinical breast examination. JAMA. 2004;292(11):1317–25.Warner E., Plewes D.B., Hill K.A. et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ul- trasound, mammography, and clinical breast examination. JAMA. 2004;292(11):1317–25.6. Kriege M., Brekelmans C.T., Boetes C. et al. Magnetic Resonance Imaging Screening Study Group. Efficacy of breast cancer screening with MRI and mammography in women with a familial or genetic predisposition. N Eng J Med 2004;351(5):427–37.Kriege M., Brekelmans C.T., Boetes C. et al. Magnetic Resonance Imaging Screening Study Group. Efficacy of breast cancer screening with MRI and mammography in women with a familial or genetic predisposition. N Eng J Med 2004;351(5):427–37.7. Lehman C.D., Blume J.D., Weatherall P. et al. International Breast MRI Consortium Work-Lehman C.D., Blume J.D., Weatherall P. et al. International Breast MRI Consortium Work-ing Group. Screening women at high risk for breast cancer with mammography and mag- netic resonance imaging. Cancer 2005;103(9):1898–905.8. Lehman C.D., Isaacs C., Schnall M.D. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institu- tion breast cancer screening study. Radiology 2007;244(2):381–8.Lehman C.D., Isaacs C., Schnall M.D. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institu- tion breast cancer screening study. Radiology 2007;244(2):381–8.9. Leach M.O., Boggis C.R., Dixon A.K. et al. MARIBS study group. Screening with mag-Leach M.O., Boggis C.R., Dixon A.K. et al. MARIBS study group. Screening with mag-netic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005;365(9473):1769–78.10. Hagen A.I., Kvistad K.A., Maehle L. et al. Sensitivity of MRI versus conventional screen- ing in the diagnosis of BRCAassociated breast cancer in a national prospective series. Breast 2007;16(4):367–74.Hagen A.I., Kvistad K.A., Maehle L. et al. Sensitivity of MRI versus conventional screen- ing in the diagnosis of BRCAassociated breast cancer in a national prospective series. Breast 2007;16(4):367–74.11. Riedl C.C., Ponhold L., Flöry D. et al. Magnetic resonance imaging of the breast im- proves detection of invasive cancer, preinvasive cancer, and premalignant lesions during sur- veillance of women at high risk for breast can- cer. Clin Cancer Res 2007;15(13):6144–52.Riedl C.C., Ponhold L., Flöry D. et al. Magnetic resonance imaging of the breast im- proves detection of invasive cancer, preinvasive cancer, and premalignant lesions during sur- veillance of women at high risk for breast can- cer. Clin Cancer Res 2007;15(13):6144–52.12. Granader E.J., Dwamena B., Carlos R.C. MRI and mammography surveillance of wom- en at increased risk for breast cancer recom- mendations using an evidence-based ap- proach. Acad Radiol 2008;15(12):1590–5.Granader E.J., Dwamena B., Carlos R.C. MRI and mammography surveillance of wom- en at increased risk for breast cancer recom- mendations using an evidence-based ap- proach. Acad Radiol 2008;15(12):1590–5.13. Samphao S., Wheeler A.J., Rafferty E. et al. Diagnosis of breast cancer in women age 40 and younger: delays in diagnosis result from underuse of genetic testing and breast imaging. Am J Surg 2009;198(4):538–43.Samphao S., Wheeler A.J., Rafferty E. et al. Diagnosis of breast cancer in women age 40 and younger: delays in diagnosis result from underuse of genetic testing and breast imaging. Am J Surg 2009;198(4):538–43.14. Sardanelli F., Podo F. Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer de- tection? Eur Radiol 2007;17(4):873–87.Sardanelli F., Podo F. Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer de- tection? Eur Radiol 2007;17(4):873–87.15. Warner E., Messersmith H., Causer P. et al. Systematic review: Using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008;148(9):671–9.Warner E., Messersmith H., Causer P. et al. Systematic review: Using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008;148(9):671–9.16. Morakkabati-Spitz N., Leutner C., Schild H. et al. Diagnostic usefulness of segmental and linear enhancement in dynamic breast MRI. Eur Radiol 2005;15(9):2010–7.Morakkabati-Spitz N., Leutner C., Schild H. et al. Diagnostic usefulness of segmental and linear enhancement in dynamic breast MRI. Eur Radiol 2005;15(9):2010–7.17. Morris E.A., Liberman L., Ballon D.J. et al. MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol 2003;181(3):619–26.Morris E.A., Liberman L., Ballon D.J. et al. MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol 2003;181(3):619–26.18. Kuhl C.K., Schrading S., Bieling H.B. et al. MRI for diagnosis of pure ductal carcinoma in situ: A prospective observational study. Lancet 2007;370(9586):485–92.Kuhl C.K., Schrading S., Bieling H.B. et al. MRI for diagnosis of pure ductal carcinoma in situ: A prospective observational study. Lancet 2007;370(9586):485–92.19. Lehman C.D., Gatsonis C., Kuhl C.K. et al. ACRIN Trial 6667 Investigators Group. MRI evaluation of the contralateral breast in womenLehman C.D., Gatsonis C., Kuhl C.K. et al. ACRIN Trial 6667 Investigators Group. MRI evaluation of the contralateral breast in womenwith recently diagnosed breast cancer. N Engl J Med. 2007;356(13):1295–303.20. Menell J.H., Morris E.A., Dershaw D.D. et al. Determination of the presence and extent of pure ductal carcinoma in situ by mammog- raphy and magnetic resonance imaging. Breast J 2005;11(6):382–90.Menell J.H., Morris E.A., Dershaw D.D. et al. Determination of the presence and extent of pure ductal carcinoma in situ by mammog- raphy and magnetic resonance imaging. Breast J 2005;11(6):382–90.21. Warner E., Hill K., Causer P. et al. Prospec- tive study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under sur- veillance with and without magnetic resonance imaging. J Clin Oncol 2011;29(13):1664–9.Warner E., Hill K., Causer P. et al. Prospec- tive study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under sur- veillance with and without magnetic resonance imaging. J Clin Oncol 2011;29(13):1664–9.22. Page D.L., Dupont W.D., Rogers L.W., Rados M.S. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985;55(11):2698–708.Page D.L., Dupont W.D., Rogers L.W., Rados M.S. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985;55(11):2698–708.23. Page D.L., Anderson T.J. Diagnostic histo- pathology of the breast. Churchill Livingstone, 1987.Page D.L., Anderson T.J. Diagnostic histo- pathology of the breast. Churchill Livingstone, 1987.24. Oprić D., Fajdić J., Hrgović Z. et al. Radial scar of the breast – a confusing lesion. Adv Med Sci 2007;52:257–61.Oprić D., Fajdić J., Hrgović Z. et al. Radial scar of the breast – a confusing lesion. Adv Med Sci 2007;52:257–61.25. Seynaeve C., Verhoog L.C., van de Bosch L.M. et al. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-con- serving therapy. Eur J Cancer 2004;40(8):1150–8.Seynaeve C., Verhoog L.C., van de Bosch L.M. et al. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-con- serving therapy. Eur J Cancer 2004;40(8):1150–8.26. Metcalfe K., Lynch H.T., Ghadirian P. et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22(12):2328–35.Metcalfe K., Lynch H.T., Ghadirian P. et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22(12):2328–35.27. Haffty B.G., Harrold E., Khan A.J. et al. Outcome of conservatively managed early-on- set breast cancer by BRCA1/2 status. Lancet 2002;359(9316):1471–7.Haffty B.G., Harrold E., Khan A.J. et al. Outcome of conservatively managed early-on- set breast cancer by BRCA1/2 status. Lancet 2002;359(9316):1471–7.